KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBITDA (2016 - 2025)

Regeneron Pharmaceuticals has reported EBITDA over the past 17 years, most recently at $853.1 million for Q4 2025.

  • Quarterly results put EBITDA at $853.1 million for Q4 2025, changed 0.41% from a year ago — trailing twelve months through Dec 2025 was $4.6 billion (up 2.33% YoY), and the annual figure for FY2025 was $4.6 billion, up 2.33%.
  • EBITDA for Q4 2025 was $853.1 million at Regeneron Pharmaceuticals, down from $1.5 billion in the prior quarter.
  • Over the last five years, EBITDA for REGN hit a ceiling of $3.1 billion in Q2 2021 and a floor of $725.7 million in Q1 2024.
  • Median EBITDA over the past 5 years was $1.2 billion (2021), compared with a mean of $1.3 billion.
  • Biggest five-year swings in EBITDA: skyrocketed 228.95% in 2021 and later plummeted 74.23% in 2022.
  • Regeneron Pharmaceuticals' EBITDA stood at $2.2 billion in 2021, then crashed by 43.77% to $1.2 billion in 2022, then rose by 1.79% to $1.3 billion in 2023, then crashed by 32.33% to $849.6 million in 2024, then rose by 0.41% to $853.1 million in 2025.
  • The last three reported values for EBITDA were $853.1 million (Q4 2025), $1.5 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.